1 of 2
1 - 5 of 172
23.04.2013
Interview with Malek Bou-Diab, Lead Portfolio Manager (In German)
18.04.2013
Biotech sector maintains upward trend in first quarter / BB Biotech outperforms its benchmark again
The biotech sector has extended its upward trend into the current year with the Nasdaq Biotechnology Index advancing another 16.7% (in USD) in the first quarter of 2013. Once again, BB Biotech beat its benchmark as it achieved a quarterly performance of 25.8% in CHF and 25.5% in EUR (including cash distribution). Core portfolio investments performed particularly well during the period under review. The biotech sector’s significant gains during the past two years have been accompanied by strong operating profit growth and therefore valuations are still reasonable. The outlook for investors remains attractive, especially considering the projected average compounded earnings growth of 20% p.a. over the next four years.
The biotech sector has extended its upward trend into the current year with the Nasdaq Biotechnology Index advancing another 16.7% (in USD) in the first quarter of 2013. Once again, BB Biotech beat its benchmark as it achieved a quarterly performance of 25.8% in CHF and 25.5% in EUR (including cash distribution). Core portfolio investments performed particularly well during the period under review. The biotech sector’s significant gains during the past two years have been accompanied by strong operating profit growth and therefore valuations are still reasonable. The outlook for investors remains attractive, especially considering the projected average compounded earnings growth of 20% p.a. over the next four years.
25.03.2013
Moneycab talks with Urs Baumann, CEO Bellevue Group.
18.03.2013
Annual General Meeting of Bellevue Group AG on 18 March 2013
All resolutions approved
At the Annual General Meeting, the shareholders of Bellevue Group AG accepted all proposals put forward by the Board of Directors.
A dividend of CHF 2.00 per share will be paid out with the share trading ex-dividend on 20 March 2013.
All resolutions approved
At the Annual General Meeting, the shareholders of Bellevue Group AG accepted all proposals put forward by the Board of Directors.
A dividend of CHF 2.00 per share will be paid out with the share trading ex-dividend on 20 March 2013.
1 of 2
